Anti Cd 20 Ocrevus denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues Non-Formulary Denials for Ocrelizumab

Blue Cross Blue Shield plans maintain tiered formularies, and ocrelizumab (Ocrevus) is placed on a specialty or non-preferred tier — or excluded outright — on some BCBS plan formularies. A non-formulary denial means the plan will not cover the drug at the standard cost-sharing level (or at all) unless the prescriber demonstrates that formulary alternatives are medically inappropriate for this patient. This is a coverage structure decision, not a clinical judgment that the drug is wrong for MS — which is why it is worth appealing.

## Why This Denial Is Appealable

Non-formulary denials are subject to the same internal-appeal and external-review rights as any other adverse benefit determination. Under ACA §2719 and ERISA §503, you have the right to a full-and-fair internal review and, if upheld, an independent external review by a certified IRO. The external-review filing window is typically around four months from the adverse determination date; verify the exact deadline in your plan documents. Expedited review (generally a 72-hour turnaround) is available when delay would seriously jeopardize health.

## Your Appeal Timeline

1. Obtain the denial letter and the plan's current formulary and coverage policy — both are available on request. 2. File a formulary exception or internal appeal — your plan is required to have a formulary-exception process; ask the insurer specifically for that pathway. 3. Document why each formulary alternative is inadequate — this is the core of a non-formulary appeal. 4. Escalate to external review if the internal appeal fails, staying within the four-month window.

## Documentation to Gather

• Formulary alternative trial history: for every drug the plan lists as a preferred alternative, provide chart records showing it was tried, the dates of use, the clinical response (or lack thereof), and the reason it was stopped.
• Intolerance or contraindication documentation: if the patient cannot safely use a formulary alternative, provide the specific chart notes, lab results, or specialist letters that support that conclusion — without relying on general population statistics.
• Prescriber exception letter: the neurologist should address each formulary alternative by name, explain why it is not appropriate for this individual patient, and state why ocrelizumab is the medically necessary choice.
• Diagnosis and severity records: MRI reports, neurology notes, and functional assessments that establish the clinical picture requiring the chosen therapy.
• Applicable guideline reference: a citation to the relevant guideline organization (e.g., the AAN or similar neurology society) supporting use of anti-CD20 therapy when alternatives have been exhausted or are contraindicated.

## Criteria-Mapping Structure

Obtain BCBS's published formulary-exception criteria and the FDA-approved prescribing label for ocrelizumab. Map each exception requirement against the chart evidence:

| Exception Requirement | Chart Evidence | Source & Date | |---|---|---| | Trial of formulary alternative(s) | Treatment records with outcomes | [Date range] | | Reason alternative is inadequate | Prescriber letter / chart notes | [Date] | | Clinical need for ocrelizumab | Neurology assessment | [Date] |

A structured, point-by-point response showing that every required element is documented gives the reviewer a clear path to approve the exception.